This is the latest episode of the free DDW narrated podcast, “Challenges and tactics for transformative drug development”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Balancing speed and quality in CLD for faster drug development”, and “Sitting down with BridgeBio Pharma”.
In the first article, Soojin Han, Chief Technical Lead and a Head of R&D at Samsung Biologics America, examines the challenges, tactics, and best partnering practices in cell line development (CLD). She emphasises the need to ensure a balance between shortening commercial CLD timelines, increasing efficiencies and maintaining product quality.
In the second article, Michael Henderson, MD, Chief Business Officer of BridgeBio Pharma, tells Lu Rahman about the company’s pursuit of transformative medicines to treat genetic diseases.